Insight into Syntekabios' AI-powered platform
Syntekabio specializes in accelerating and optimizing drug development through the use of artificial intelligence (AI). This is intended in particular to help reduce costs and shorten the time to market for new therapies.
The company relies on its proprietary DeepMatcher® platform, which covers the entire process from identifying suitable target proteins to providing IND-ready candidates. With the “Develop Now, Pay Later” offering, Syntekabio enables pharmaceutical and biotechnology companies to test the benefits of a target protein without any upfront financial investment. If a project is promising, the STB LaunchPad program is activated to generate optimized compounds and clinical candidates.
The STB LaunchPad and the role of AI
The STB LaunchPad program is a central part of Syntekabio's innovation strategy. It is based on DeepMatcher® technology, an advanced AI platform that combines machine learning (ML) algorithms and biological expertise. This platform uses based physics approaches and proprietary data models to identify potential active ingredients with high precision.
The integration of AI enables continuous generation of drug candidates, including first-in-class and best-in-class molecules. Leveraging a global network of contract research organizations (CROs) ensures that the platform's results are fully validated. This model offers both standardized and tailored solutions for specific target proteins and indications.
“Develop Now, Pay Later”: A flexible business model
With the “Develop Now, Pay Later” approach, Syntekabio addresses the special needs of small and medium-sized biotech companies, which often work with limited resources. This strategy reduces financial barriers to entry and offers companies the opportunity to test innovative technologies without immediate costs. The long-term collaboration is based on projects with a high chance of success being further developed in a phase in which economic benefits arise.
Syntekabio's contribution to global drug development
Since its founding in 2009, Syntekabio has pursued the goal of combining biological research and artificial intelligence. With the company's proprietary supercomputer cloud system and a scalable network of CROs, the company has the capacity to work on multiple projects simultaneously. Syntekabio emphasizes that the platform's approach is not limited to specific disease areas, increasing flexibility for a wide range of applications.
CEO Dr. Jongsun Jung said in a statement that Syntekabio would like to intensify dialogue with industry leaders and partners at the Biotech Showcase 2025. The company sees great potential in the collaboration to make drug development more efficient and accessible on a global scale.
FAQs about the Biotech Showcase 2025 and Syntekabio
- What is the Biotech Showcase?
The Biotech Showcase is a leading industry event held annually in San Francisco. It offers a platform for companies, investors and scientists to present innovations in biotechnology and promote collaborations. - Which technologies does Syntekabio present?
Syntekabio presents its AI-powered DeepMatcher® platform that supports the entire drug discovery process, from target identification to the delivery of IND-ready candidates. - How does the “Develop Now, Pay Later” model work?
Companies can use Syntekabio's platform to analyze target proteins without incurring upfront costs. Further investments were only made when feasibility was proven.
